May 2, 2024 7:46am
During “earning’s” season, traders vote by buying and selling shares; in the short run trades are dictated by meeting “street” expectation including LPS (loss-per-share) as compared to few if ever net income
Earnings: Alnylam Pharmaceuticals (ALNY), Ultragenyx Pharmaceuticals (RARE), AxoGen (AXGN), Blueprint Medicine (BPMC)
I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing money in your portfolio for the short and near-term
Never leave an investor uninformed!
Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi.
Thursday: The pre-open Dow futures are UP +0.42% or (+161 points), the S&P futures are UP +0.66% or (+33 pints) as the Nasdaq futures are UP +0.87% or (+151 points)
Stock futures ascended on Thursday 5/2/24,
European stocks were slightly lower,
Asia-Pacific markets were mixed.
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Wednesday: The Dow closed UP+87.37 points or +0.23%, the S&P closed DOWN -17.30 points or -0.34% while the Nasdaq closed DOWN -52.34 points or -0.33%
Economic Data Docket: weekly jobless claims, first-quarter worker productivity and unit labor costs, as well as March figures on the trade deficit and factory orders.
- Challenger jobs cuts, year-over-year, April (+0.7% previously) Unit labor costs, Q1 (+2% expected, +0.4% previously);
- Nonfarm productivity, first quarter (+1.5%% expected, +3.2% previously);
- Weekly initial jobless claims (217,00 previously);
- Factory orders, March (+1.6% expected, +1.4% previously);
- Durable goods orders, March final (2.6% previously)
Wednesday night’s RegMed Investors (RMi) Closing Bell: “the path forward. Cruising to more 4 earnings tomorrow as Fed suggests it would be appropriate to cut rates "at some point" this year.”… https://www.regmedinvestors.com/articles/13443
Q2/24: May – 1 positive close
- April - 16 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Yet again, I am passing on forecasting the daily indications is focused on inflation-oriented durable goods jobs and non-farm productivity report “numbers” the aftermarket fluctuated as the pre-open waits for the all-clear alarm, … it is still a mix of ups, downs and just unknowns.
“I remain a skeptic, as electronic trading remains the impetus to, <I believe> the cell and gene therapy sector getting artificial high and low” … as proven in past sessions!
The BOTTOM LINE: The cell and gene therapy sector is still in play as earning season comes with an air-sock waiting for the wind …
- The cell and gene therapy sector ascended to positive territory Wednesday, closed negative on Tuesday and closed positive on Monday, closing positive on last Friday while closing down on the previous Thursday.
Wednesday, the stock market rally attempt had a wild afternoon. The major indexes rose sharply after the Fed agreed to slow the pace of balance sheet reductions while Fed chief Powell a non-committal tone. But in the final hour indexes slashed gains, closing mixed. <IBD>
“I hate to be negative or contrarian but, this is a NO spin zone and pricing truth is its product; I can always be WRONG but, I am mostly EARLY!”
Q1/24 Reporting Season:
- Ionis Pharmaceuticals (IONS) and Agenus (AGEN) on Tuesday, 5/7,
- Editas medicine (EDIT), Lenz therapeutics (LENZ), Vericel (VCEL), Regenxbio (RGNX) on Wednesday, 5/8
- BioLife Solutions (BLFS), Intellia Therapeutics (NTLA) on Thursday, 5/9
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
